VIDEO | Proactive Investors – May 2023

Orthocell’s MD Paul Anderson and John Van Der Wielen spoke with Andrew Scott at Proactive Investors about John’s appointment as independent non-executive chairman. John brings 35 years of global experience in wealth management, private banking, investments and health insurance, including considerable experience in corporate strategy, international growth initiatives, M&A transactions and engaging strategic investors.

Appointment of John Van Der Wielen as Independent Non-Executive Chairman

Orthocell has announced the appointment of Mr. John Van Der Wielen as Orthocell’s new independent Non-Executive Chairman, effective June 1, 2023.

Mr. Van Der Wielen is a globally recognised executive with a passion for supporting innovative life science companies and for enhancing Australia’s capacity to translate local innovations into products that make a difference to clinical practice and patients’ lives.

He has over 35 years’ international experience in wealth management, private banking, investments, and insurance, and has held senior executive positions with several national and global financial services groups. Most recently Mr. Van Der Wielen was CEO and MD of HBF Health Ltd for over five years.

John Van Der Wielen said:

“I am very excited to be joining the senior leadership team at Orthocell at this pivotal stage in the Company’s development. I have been monitoring the Company’s significant progress including its recent landmark licensing deal with BioHorizons. I believe Orthocell is now extremely well placed to drive shareholder value by actively supporting distribution partners to ramp up sales in existing and additional international markets, and to advance the commercialisation of its truly unique regenerative medicine portfolio.”

Click here to read today’s ASX release.

Veritas Securities Equity Research Report | April 2023

Veritas Securities Limited has released an Equity Research report valuing Orthocell (ASX: OCC) at A$0.90 per share.

The report summarises the commercial potential of Orthocell’s novel orthopaedic repair technology and its advanced product pipeline, as well as the competitive advantages and revenue opportunities associated with its Striate™ and Remplir™ products – especially in the US.

Describing the Company as being on the cusp of widespread adoption, the author noted:

“The wait looks to be over for Orthocell investors. It typically takes 7-12 years for a novel medical treatment to contribute meaningful revenues. It is now 8 years since the Company commenced the pilot CelGro study. With the validation of the CelGro platform from the BioHorizons deal and scale up of manufacturing capacity recently completed, the transition to a global medical device manufacturer has begun.”

The report also highlights the strengths of the leadership team, noting “the board and executive team of Orthocell contains the right mix of scientific and commercial expertise for the next phase of growth.”

Click here to read the Equity Research report.

Commencement of Nerve Repair Study

Orthocell (ASX:OCC) has announced the commencement of a nerve repair study aimed at supporting product marketing initiatives and international regulatory and reimbursement strategies for its nerve repair device, Remplir.

The comparator study aims to evaluate the safety, mechanism of action and product performance of Remplir™, when used as a nerve wrap in peripheral nerve repair, compared to traditional repair methods. The study forms part of a comprehensive pre-clinical and clinical development program in nerve repair and regeneration and will be conducted in collaboration with leading orthopaedic researcher, Professor Bill Walsh, at the University of New South Wales.

 Orthocell Managing Director, Paul Anderson, said: 

Remplir has shown, in previous studies, to be the superior product for nerve regeneration when compared to an FDA-approved comparator device. We are confident that the outcomes of this study will be consistent with the clinical performance of Remplir to date, and validate that Remplir is easier to use, reduces the need for sutures and results in more consistent and predictable return of muscle function.”

Click here to read today’s ASX release.